Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD9291 in EGFR exon 20 insertion mutations

Trial Profile

AZD9291 in EGFR exon 20 insertion mutations

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms AEX20
  • Most Recent Events

    • 26 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 05 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top